<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Epilepsia Open</journal-id>
<journal-id journal-id-type="iso-abbrev">Epilepsia Open</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)2470-9239</journal-id>
<journal-id journal-id-type="publisher-id">EPI4</journal-id>
<journal-title-group>
<journal-title>Epilepsia Open</journal-title>
</journal-title-group>
<issn pub-type="epub">2470-9239</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29588991</article-id>
<article-id pub-id-type="pmc">5839317</article-id>
<article-id pub-id-type="doi">10.1002/epi4.12085</article-id>
<article-id pub-id-type="publisher-id">EPI412085</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Short Research Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Short Research Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Early‐onset epileptic encephalopathy and severe developmental delay in an association with de novo double mutations in <italic>NF1</italic> and <italic>MAGEL2</italic>
</article-title>
<alt-title alt-title-type="left-running-head">S. Akamine et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="epi412085-cr-0001">
<name>
<surname>Akamine</surname>
<given-names>Satoshi</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="bio" rid="epi412085-biog-0001">*</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0002">
<name>
<surname>Sagata</surname>
<given-names>Noriaki</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="epi412085-cr-0003">
<name>
<surname>Sakai</surname>
<given-names>Yasunari</given-names>
</name>
<address>
<email>ysakai22q13@gmail.com</email>
</address>
<xref ref-type="aff" rid="epi412085-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0004">
<name>
<surname>Kato</surname>
<given-names>Takahiro A.</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="epi412085-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0005">
<name>
<surname>Nakahara</surname>
<given-names>Takeshi</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0006">
<name>
<surname>Matsushita</surname>
<given-names>Yuki</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0007">
<name>
<surname>Togao</surname>
<given-names>Osamu</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0008">
<name>
<surname>Hiwatashi</surname>
<given-names>Akio</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0009">
<name>
<surname>Sanefuji</surname>
<given-names>Masafumi</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0010">
<name>
<surname>Ishizaki</surname>
<given-names>Yoshito</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0011">
<name>
<surname>Torisu</surname>
<given-names>Hiroyuki</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="epi412085-aff-0006">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0012">
<name>
<surname>Saitsu</surname>
<given-names>Hirotomo</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0007">
<sup>7</sup>
</xref>
<xref ref-type="aff" rid="epi412085-aff-0008">
<sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0013">
<name>
<surname>Matsumoto</surname>
<given-names>Naomichi</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0007">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0014">
<name>
<surname>Hara</surname>
<given-names>Toshiro</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0009">
<sup>9</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0015">
<name>
<surname>Sawa</surname>
<given-names>Akira</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0010">
<sup>10</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0016">
<name>
<surname>Kano</surname>
<given-names>Shinichi</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0011">
<sup>11</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0017">
<name>
<surname>Furue</surname>
<given-names>Masutaka</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0018">
<name>
<surname>Kanba</surname>
<given-names>Shigenobu</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0019">
<name>
<surname>Shaw</surname>
<given-names>Chad A.</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0012">
<sup>12</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi412085-cr-0020">
<name>
<surname>Ohga</surname>
<given-names>Shouichi</given-names>
</name>
<xref ref-type="aff" rid="epi412085-aff-0001">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="epi412085-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Pediatrics</named-content>
<named-content content-type="organisation-division">Graduate School of Medical Sciences</named-content>
<institution>Kyushu University</institution>
<named-content content-type="city">Fukuoka</named-content>
<country country="JP">Japan</country>
</aff>
<aff id="epi412085-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Neuropsychiatry</named-content>
<named-content content-type="organisation-division">Graduate School of Medical Sciences</named-content>
<institution>Kyushu University</institution>
<named-content content-type="city">Fukuoka</named-content>
<country country="JP">Japan</country>
</aff>
<aff id="epi412085-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Innovation Center for Medical Redox Navigation</named-content>
<named-content content-type="organisation-division">Graduate School of Medical Sciences</named-content>
<institution>Kyushu University</institution>
<named-content content-type="city">Fukuoka</named-content>
<country country="JP">Japan</country>
</aff>
<aff id="epi412085-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Dermatology</named-content>
<named-content content-type="organisation-division">Graduate School of Medical Sciences</named-content>
<institution>Kyushu University</institution>
<named-content content-type="city">Fukuoka</named-content>
<country country="JP">Japan</country>
</aff>
<aff id="epi412085-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Department of Radiology</named-content>
<named-content content-type="organisation-division">Graduate School of Medical Sciences</named-content>
<institution>Kyushu University</institution>
<named-content content-type="city">Fukuoka</named-content>
<country country="JP">Japan</country>
</aff>
<aff id="epi412085-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Section of Pediatrics</named-content>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Fukuoka Dental College</institution>
<named-content content-type="city">Fukuoka</named-content>
<country country="JP">Japan</country>
</aff>
<aff id="epi412085-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">Department of Human Genetics</named-content>
<institution>Yokohama City University Graduate School of Medicine</institution>
<named-content content-type="city">Yokohama</named-content>
<country country="JP">Japan</country>
</aff>
<aff id="epi412085-aff-0008">
<label><sup>8</sup></label>
<named-content content-type="organisation-division">Department of Biochemistry</named-content>
<institution>Hamamatsu University School of Medicine</institution>
<named-content content-type="city">Hamamatsu</named-content>
<country country="JP">Japan</country>
</aff>
<aff id="epi412085-aff-0009">
<label><sup>9</sup></label>
<institution>Fukuoka Children's Hospital</institution>
<named-content content-type="city">Fukuoka</named-content>
<country country="JP">Japan</country>
</aff>
<aff id="epi412085-aff-0010">
<label><sup>10</sup></label>
<named-content content-type="organisation-division">Departments of Psychiatry</named-content>
<named-content content-type="organisation-division">Mental Health, Neuroscience, and Biomedical Engineering</named-content>
<institution>Johns Hopkins University School of Medicine and Bloomberg School of Public Health</institution>
<named-content content-type="city">Baltimore</named-content>
<named-content content-type="country-part">Maryland</named-content>
<country country="US">U.S.A.</country>
</aff>
<aff id="epi412085-aff-0011">
<label><sup>11</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry and Behavioral Sciences</named-content>
<institution>Johns Hopkins University School of Medicine and Bloomberg School of Public Health</institution>
<named-content content-type="city">Baltimore</named-content>
<named-content content-type="country-part">Maryland</named-content>
<country country="US">U.S.A.</country>
</aff>
<aff id="epi412085-aff-0012">
<label><sup>12</sup></label>
<named-content content-type="organisation-division">Department of Molecular and Human Genetics</named-content>
<institution>Baylor College of Medicine</institution>
<named-content content-type="city">Houston</named-content>
<named-content content-type="country-part">Texas</named-content>
<country country="US">U.S.A.</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label>Address correspondence to Yasunari Sakai, Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812‐8582, Japan. E‐mail: <email>ysakai22q13@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>23</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<month>3</month>
<year>2018</year>
</pub-date>
<volume>3</volume>
<issue>1</issue>
<issue-id pub-id-type="doi">10.1002/epi4.2018.3.issue-1</issue-id>
<fpage>81</fpage>
<lpage>85</lpage>
<history>
<date date-type="accepted">
<day>14</day>
<month>10</month>
<year>2017</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 International League Against Epilepsy <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2017 The Authors. <italic>Epilepsia Open</italic> published by Wiley Periodicals Inc. on behalf of International League Against Epilepsy.</copyright-statement>
<license license-type="creativeCommonsBy-nc-nd">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution‐NonCommercial‐NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:EPI4-3-81.pdf" xlink:type="simple"></self-uri>
<abstract id="epi412085-abs-0001">
<title>Summary</title>
<p>Advance in the exome‐wide sequencing analysis contributes to identifying hundreds of genes that are associated with early‐onset epileptic encephalopathy and neurodevelopmental disorders. On the basis of massive sequencing data, functional interactions among different genes are suggested to explain the common molecular pathway underlying the pathogenic process of these disorders. However, the relevance of such interactions with the phenotypic severity or variety in an affected individual remains elusive. In this report, we present a 45‐year‐old woman with neurofibromatosis type 1 (NF1), infantile‐onset epileptic encephalopathy, and severe developmental delay. Whole‐exome sequencing identified de novo pathogenic mutations in <italic>NF1</italic> and the Schaaf‐Yang syndrome‐associated gene, <italic>MAGEL2</italic>. Literature‐curated interaction data predicted that NF1 and MAGEL2 proteins were closely connected in this network via their common interacting proteins. Direct conversion of fibroblasts into neurons in vitro showed that neuronal cells from 9 patients with NF1 expressed significantly lower levels of <italic>MAGEL2</italic> (54%, p = 0.0047) than those from healthy individuals. These data provide the first evidence that pathogenic mutations of <italic>NF1</italic> deregulate the expression of other neurodevelopmental disease‐associated genes. De novo mutations in multiple genes may lead to severe developmental phenotypes through their cumulative effects or synergistic interactions.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="epi412085-kwd-0001">Early‐onset epileptic encephalopathy</kwd>
<kwd id="epi412085-kwd-0002">Whole‐exome sequencing</kwd>
<kwd id="epi412085-kwd-0003">De novo mutation</kwd>
<kwd id="epi412085-kwd-0004">Neurofibromatosis type 1</kwd>
<kwd id="epi412085-kwd-0005"><styled-content style="fixed-case">MAGEL</styled-content>2</kwd>
<kwd id="epi412085-kwd-0006">Direct conversion</kwd>
<kwd id="epi412085-kwd-0007">Functional interaction</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>JSPS KAKENHI</funding-source>
<award-id>15K0962</award-id>
<award-id>26461547</award-id>
</award-group>
<award-group>
<funding-source>Ministry of Health, Labour and Welfare of Japan</funding-source>
</award-group>
<award-group>
<funding-source>Life Science Foundation of Japan</funding-source>
</award-group>
<award-group>
<funding-source>Takeda Science Foundation</funding-source>
</award-group>
<award-group>
<funding-source>Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics</funding-source>
</award-group>
<award-group>
<funding-source>Japan Epilepsy Research Foundation</funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="1"></table-count>
<page-count count="5"></page-count>
<word-count count="3339"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>epi412085</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>March 2018</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.2.2 mode:remove_FC converted:01.03.2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<p>Neurofibromatosis type 1 (NF1) is a neurocutaneous syndrome with autosomal dominant patterns of inheritance.<xref ref-type="ref" rid="epi412085-bib-0001">1</xref> Affected individuals show characteristic skin lesions of café‐au‐lait spots, multiple tumors, and variable degree of mental disability with or without autistic features. The <italic>NF1</italic> gene is located at chromosome 17q11.2, encoding 2,839 amino acid protein neurofibromin.<xref ref-type="ref" rid="epi412085-bib-0002">2</xref>
<italic>NF1</italic> mutations cause the hyperactive extracellular signal‐regulated kinase (ERK) pathway, thereby leading to accelerated cell growth and tumor formation.<xref ref-type="ref" rid="epi412085-bib-0003">3</xref> Hyperactive signals in synaptic ERK pathways are associated with both epilepsy and mental development in childhood.<xref ref-type="ref" rid="epi412085-bib-0004">4</xref> Previous studies demonstrated that the prevalence (0.76%) of infantile spasm (IS) or early‐onset epileptic encephalopathy (EOEE) in NF1 has been reported to be higher than those (0.02–0.05%) in general populations.<xref ref-type="ref" rid="epi412085-bib-0005">5</xref> Neuroimaging studies also revealed that cortical and subcortical lesions were occasionally found in NF1 patients.<xref ref-type="ref" rid="epi412085-bib-0006">6</xref> However, specific brain lesions or genetic backgrounds have not been disclosed for NF1 in the majority of cases with IS/EOEE. We experienced a case of a 45‐year‐old female with NF1, EOEE, and severe developmental delay. Atypical phenotypes in the present case were studied on the basis of genetic as well as biological backgrounds.</p>
<sec id="epi412085-sec-0002">
<title>Materials and Methods</title>
<p>This study was approved by the Institutional Review Board at Kyushu University (#461‐00). Written informed consent was obtained from the parents. Experiments were conducted under a stringent compliance to the institutional guideline and our experimental protocol (23‐53). Case report and experimental procedures for whole‐exome sequencing (WES), in vitro conversion of neurons, quantitative polymerase chain reactions (PCR), and bioinformatics are presented in Appendix <xref ref-type="supplementary-material" rid="epi412085-sup-0004">S1</xref> and Figs. <xref ref-type="supplementary-material" rid="epi412085-sup-0001">S1</xref>, <xref ref-type="supplementary-material" rid="epi412085-sup-0002">S2</xref>).</p>
</sec>
<sec id="epi412085-sec-0003">
<title>Results</title>
<sec id="epi412085-sec-0004">
<title>De novo mutations in <italic>NF1</italic> and <italic>MAGEL2</italic>
</title>
<p>De novo mutations in <italic>NF1</italic> (<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NM001042492">NM001042492</ext-link>.2: c.4835 + 1G&gt;T) and <italic>MAGEL2</italic> (<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NM019066.2">NM019066.2</ext-link>: c.219C&gt;G, c.224delC) were validated with Sanger sequencing (Figs. <xref ref-type="fig" rid="epi412085-fig-0001">1</xref>A,B). The former mutation occurred at the splicing junction of exon 36 in <italic>NF1</italic>, disrupting the functional expression of neurofibromin. The latter was mapped to the coding region of <italic>MAGEL2</italic> and was considered to produce a truncated form of MAGEL2. We further investigated whether the mutated allele was located on the paternal allele.<xref ref-type="ref" rid="epi412085-bib-0007">7</xref> Methylation‐sensitive digestion with <italic>Sma</italic>I followed by PCR amplification and direct sequencing of the flanking region revealed that the mutated allele remained intact after the <italic>Sma</italic>I digestion (Fig. <xref ref-type="fig" rid="epi412085-fig-0001">1</xref>B). We thus confirmed that the de novo <italic>MAGEL2</italic> mutation occurred at the maternal allele, which was fully methylated in lymphocytes. Microarray‐based comparative genome hybridization (CMA ver. 8.1 at Baylor MGL; data not shown) excluded that this case carried pathogenic copy number variants (CNVs).</p>
<fig fig-type="Figure" id="epi412085-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>De novo mutations identified in the present case and functional interaction between <italic>NF1</italic> and <italic>MAGEL2</italic>. (<bold>A</bold>) <italic>De novo</italic> mutation at the splicing junction of exon 36 in <italic>NF1</italic>. The sequence chromatograms of father, mother, and the patient are shown. Red arrow indicates that this mutation occurred at chr17:29592358 (<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NM_001042492">NM_001042492</ext-link>.2:c.4835 + 1G&gt;T). Boxed letters above the sequencing data denote exonic sequences. (<bold>B</bold>) <italic>MAGEL2</italic> mutation in the present case. Aligned data illustrate that the mutation occurred de novo in this patient at chr15:23892666, 23892671 (<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NM_019066.4">NM_019066.4</ext-link>:c.219C&gt;G, c.224delC). Sequencing results before (<italic>Sma</italic>I<sup>−</sup>) and after the <italic>Sma</italic>I digestion (<italic>Sma</italic>I<sup>+</sup>) indicate that this mutation occurred at the methylated (or maternally inherited) allele. (<bold>C</bold>) <italic>MAGEL2</italic> mRNA expression before and after neuronal induction. White and black bar plots represent the relative expression levels in indicated cells from healthy controls (n = 9) and NF1 patients (n = 9), respectively. (<bold>D</bold>) <italic>CYFIP1</italic> and <italic>UBE3A</italic> expressions in fibroblasts and induced neurons. The gene expression profiles were quantitated in vitro using the cells from healthy controls and NF1 patients (n = 9 for each group). Values in C and D are shown as mean ± SD of each group. Asterisk indicates the p value of less than 0.05 (Student's t test).</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="EPI4-3-81-g001"></graphic>
</fig>
</sec>
<sec id="epi412085-sec-0005">
<title>Functional interaction between NF1 and MAGEL2</title>
<p>The de novo <italic>MAGEL2</italic> mutation in this case was unlikely a primary cause of the patient's developmental phenotypes. We considered the double mutations of <italic>NF1</italic> and <italic>MAGEL2</italic> as an extremely rare genetic event<xref ref-type="ref" rid="epi412085-bib-0008">8</xref> (Table <xref ref-type="table-wrap" rid="epi412085-tbl-0001">1</xref>). We alternatively interpreted this event to be possibly relevant with the unusual NF1 phenotype of this case. To explore whether NF1 and MAGEL2 might work as genetic modifiers for each other, we used STRING, a protein‐protein interaction database (<ext-link ext-link-type="uri" xlink:href="http://string-db.org/">http://string-db.org/</ext-link>). This open database predicted that NF1 and MAGEL2 were directly or indirectly connected via common binding proteins in a functional network consisting of 35 proteins (nodes) and 84 interactions (edges) (Fig. <xref ref-type="supplementary-material" rid="epi412085-sup-0002">S2</xref>A). Given the number of edges expected to be 48, these 35 proteins were considered to have 1.8‐fold enriched protein‐protein interactions (p = 2.25 × 10<sup>−6</sup>). Thus, this network was suggested to have functional enrichment in certain molecular pathways. Indeed, the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses showed that signaling molecules associated with “chromatin binding (GO:0003682),” “RNA polymerase (GO:0003899 and KEGG:3020),” and “RAS signaling pathways (KEGG:4014)” were enriched in this network (Figs. <xref ref-type="supplementary-material" rid="epi412085-sup-0002">S2</xref>B,C).</p>
<table-wrap id="epi412085-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Clinical features of the present case in comparison with those of neurofibromatosis type 1 and Schaaf‐Yang syndrome</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="center" colspan="1" rowspan="1" valign="top">Present case</th>
<th align="center" colspan="1" rowspan="1" valign="top">Neurofibromatosis type 1</th>
<th align="center" colspan="1" rowspan="1" valign="top">Schaaf‐Yang syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Mutated gene</td>
<td align="char" colspan="1" rowspan="1">
<italic>NF1, MAGEL2</italic>
</td>
<td align="char" colspan="1" rowspan="1">
<italic>NF1</italic>
</td>
<td align="char" colspan="1" rowspan="1">
<italic>MAGEL2</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">(Band Locus)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="char" colspan="1" rowspan="1">(17q11.2)</td>
<td align="char" colspan="1" rowspan="1">(15q11.2)</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1">Phacomatosis and associated lesion</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Café‐au‐lait spots</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Neurofibroma</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Lisch nodules of iris</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1">Dysmorphism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Bitemporal narrowing of facial appearance</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
<td align="char" colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Almond‐shaped palpebral fissures</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
<td align="char" colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Small hands</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
<td align="char" colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Joint contractures</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
<td align="char" colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1">Tumorigenesis and skeletal problem</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Brain tumor</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Abnormal MRI signal</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Bone fracture</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1">Neurological sign</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Feeding problem</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
<td align="char" colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Hypotonia</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Developmental delay</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Autism spectrum disorder</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Seizure</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" colspan="1" rowspan="1">+</td>
<td align="char" char=" " colspan="1" rowspan="1">−</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
<sec id="epi412085-sec-0006">
<title>Altered expression of MAGEL2 in NF1 patient‐derived neurons</title>
<p>To validate the possible functional interplays between NF1 and MAGEL2, we examined whether pathogenic mutations in <italic>NF1</italic> might influence neuronal expression of <italic>MAGEL2</italic>. We determined the transcriptional activation of <italic>NF1</italic> and <italic>MAGEL2</italic> using the direct conversion system of fibroblast into neuron in vitro. Quantitative analyses on mRNA expression showed that <italic>MAGEL2</italic> expressions in fibroblasts did not differ between the patients and controls. The neuronal conversion induced robust increase in the <italic>MAGEL2</italic> expression (Fig. <xref ref-type="fig" rid="epi412085-fig-0001">1</xref>C). Notably, the neuronal expression of <italic>MAGEL2</italic> was decreased to 54% of that in healthy controls (n = 9 for each group, p = 0.0047, Student's t test; Fig. <xref ref-type="fig" rid="epi412085-fig-0001">1</xref>C). The neuronal expression of <italic>MAGEL2</italic> in the present case was 41% of that in healthy controls (p = 0.0189, Student's t test; data not shown). Neuronal conversion also induced higher expressions of imprinted genes (<italic>UBE3A</italic> and <italic>CYFIP1</italic>) at the chromosome 15p11.2 region than those in fibroblasts (Fig. <xref ref-type="fig" rid="epi412085-fig-0001">1</xref>D). However, induced neurons from NF1 patients and healthy controls expressed these genes at comparable levels. These data confirmed the epistatic regulation of <italic>MAGEL2</italic> expression by NF1 and illustrated the specific effects of the <italic>NF1</italic> mutations on transcriptional activation of <italic>MAGEL2</italic> during the neuronal conversion.</p>
<p>To test whether <italic>NF1</italic> mutations might affect other genes associated with EOEE, we randomly selected 6 EOEE‐associated genes (<italic>CDKL5, CHD2, ARX</italic>,<italic> KCNT1</italic>,<italic> SCN1A,</italic> and <italic>TRIM8</italic>)<xref ref-type="ref" rid="epi412085-bib-0009">9</xref>, <xref ref-type="ref" rid="epi412085-bib-0010">10</xref>, <xref ref-type="ref" rid="epi412085-bib-0011">11</xref>, <xref ref-type="ref" rid="epi412085-bib-0012">12</xref>, <xref ref-type="ref" rid="epi412085-bib-0013">13</xref> and assessed their expression profiles in both fibroblasts and induced neurons (Fig. <xref ref-type="supplementary-material" rid="epi412085-sup-0003">S3</xref>). As expected, in vitro conversion of fibroblasts into neurons resulted in 2‐ to 5‐fold higher expression of these six genes than those in fibroblasts. When we compared their expression levels in neurons, only <italic>KCNT1</italic> was expressed at a significantly lower level (69%) in NF1 neurons than that in healthy controls (p = 0.011, Student's t test; Fig. <xref ref-type="supplementary-material" rid="epi412085-sup-0003">S3</xref>). All the other genes were expressed in neurons from NF1 patients at similar levels to those in controls. These data suggested that <italic>NF1</italic> mutation attenuated the expression of a subset of EOEE‐associated genes.</p>
</sec>
</sec>
<sec id="epi412085-sec-0007">
<title>Discussion</title>
<p>We presented a Japanese woman who had dysmorphic appearance, severe intellectual disability, and intractable epilepsy with a history of infantile‐onset seizures. This is the first case of NF1 carrying another de novo mutation in a gene that is known to cause different neurodevelopmental disorders. Previous studies demonstrated that NF1 patients are susceptible to the onset of epileptic encephalopathy, such as IS and EOEE.<xref ref-type="ref" rid="epi412085-bib-0014">14</xref>
</p>
<p>The WES and subsequent analyses led us to the following two discussions: First, the severe phenotypes of this patient resulted solely from the <italic>NF1</italic> mutation regardless of the <italic>MAGEL2</italic> mutation. Second, the double mutations in <italic>NF1</italic> and <italic>MAGEL2</italic> exerted cumulative or synergistic effects to produce more severe phenotypes than those expected for individuals with a single gene mutation in either <italic>NF1</italic> or <italic>MAGEL2</italic>.</p>
<p>The first perspective might be valid taking the allele‐specific expression of <italic>MAGEL2</italic> into account. Indeed, truncating <italic>MAGEL2</italic> mutations proved to be critical for dysmorphic appearance and hypothalamic dysfunctions exclusively when the mutations occurred in the paternal alleles.<xref ref-type="ref" rid="epi412085-bib-0007">7</xref> Despite these facts, experimental studies have shown that <italic>MAGEL2</italic> was widely expressed in embryonic as well as in the adult brains.<xref ref-type="ref" rid="epi412085-bib-0015">15</xref> Moreover, allele‐specific expression of imprinted genes varies over time and by region in neuronal subpopulations.<xref ref-type="ref" rid="epi412085-bib-0015">15</xref> Recent studies have shown that <italic>MAGEL2</italic> and <italic>NF1</italic> were expressed from the maternal allele in embryonic tissues under certain conditions, suggesting that Prader‐Willi syndrome–associated genes in the chromosomal region at 15q11–q13 have epigenetic flexibility.<xref ref-type="ref" rid="epi412085-bib-0016">16</xref>, <xref ref-type="ref" rid="epi412085-bib-0017">17</xref> With our findings of lower expression of <italic>MAGEL2</italic> in neurons from NF1 patients, we considered that the <italic>MAGEL2</italic> mutation on the maternal allele caused only negligible effects on neuronal phenotype, whereas it could reach the pathogenic level when the additional mutation in <italic>NF1</italic> coincided. Therefore, it cannot be safely concluded that the <italic>MAGEL2</italic> mutation in the maternal allele was irrelevant to the neurodevelopmental phenotypes in this case.</p>
<p>MAGEL2 protein belongs to a family of melanoma‐associated antigen (MAGE) domain‐containing molecules, which has been characterized as highly expressed genes/proteins in various types of tumors.<xref ref-type="ref" rid="epi412085-bib-0018">18</xref> Among MAGE family proteins, NRAGE was shown to interact with p75 neurotrophin receptor and to promote nerve growth factor (NGF)‐dependent apoptosis, suggesting that NRAGE could be a component of intracellular signaling pathways.<xref ref-type="ref" rid="epi412085-bib-0019">19</xref> Similarly, NF1 is involved in the NGF‐dependent survival of embryonic sensory and sympathetic neurons.<xref ref-type="ref" rid="epi412085-bib-0020">20</xref> These data supported our hypothesis that MAGE family proteins and NF1 may cooperatively regulate the maturation of neurons under certain molecular pathways, as the network in this study illustrated.</p>
<p>The interaction database and subsequent bioinformatics analysis revealed that the NF1‐ and MAGEL2‐containing network was significantly enriched in the proteins associated with particular cellular functions, such as RAS signaling. Although physiological functions of MAGEL2 in neurons remain unknown, this result raised a new possibility that MAGEL2 may regulate the RAS signals cooperatively with NF1 in the developing brain. Thus, the hypomorphic mutations in the two genes may cause more profound effects on neuronal dysfunctions than those resulting from the mutation in either gene.</p>
<p>According to the protein interaction database, NF1 and MAGEL2 were unlikely to constitute a protein complex. Rather, our experimental data supported evidence that NF1 acts as an epistatic regulator of <italic>MAGEL2</italic> expression. In line with these data, we conceptualized that the de novo mutation of <italic>MAGEL2</italic> exaggerated neuronal dysfunctions owing to the <italic>NF1</italic> mutation and hyperactive RAS‐ERK signaling. Thus, the severe neurological phenotype of our case can be regarded as an extended model of digenic inheritance or the transheterozygote at two loci.<xref ref-type="ref" rid="epi412085-bib-0021">21</xref>, <xref ref-type="ref" rid="epi412085-bib-0022">22</xref> To determine their additive or synergistic effects on RAS signaling and neurological deficits, more studies using genetically engineered mice will be necessary.</p>
<p>Missing pieces are left for our future study to investigate whether and how recessive mutations inherited from the patient's parents could modify the phenotypes of other cases with atypical phenotypes of NF1. Accumulation of genome‐wide analysis data for NF1 patients with IS and EOEE will clarify these issues.</p>
</sec>
<sec id="epi412085-sec-0009">
<title>Disclosure</title>
<p>None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data" id="epi412085-sup-0001">
<caption>
<p>
<bold>Figure S1</bold>. Dysmorphic appearance of the present case.</p>
</caption>
<media xlink:href="EPI4-3-81-s001.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="epi412085-sup-0002">
<caption>
<p>
<bold>Figure S2</bold>. Bioinformatics analyses on interaction between <italic>NF1</italic> and <italic>MAGEL2</italic>.</p>
</caption>
<media xlink:href="EPI4-3-81-s002.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="epi412085-sup-0003">
<caption>
<p>
<bold>Figure S3</bold>. Expression of epileptic encephalopathy‐associated genes in fibroblasts and induced neurons.</p>
</caption>
<media xlink:href="EPI4-3-81-s003.tif">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="epi412085-sup-0004">
<caption>
<p>
<bold>Appendix S1</bold>. Materials and methods.</p>
</caption>
<media xlink:href="EPI4-3-81-s004.docx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack id="epi412085-sec-0008">
<title>Acknowledgments</title>
<p>We thank Huda Y. Zoghbi, Christian P. Schaaf (Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital), and Ryutaro Kira (Fukuoka Children's Hospital) for helpful discussion, and Kenjiro Gondo (Gondo Pediatric Clinic) for continual support of the patient and her family. This study was supported by JSPS KAKENHI grant numbers 15K0962 (Y.S.), 16K09991 (M.S.), evidence‐based early diagnosis and treatment strategies for neuroimmunological diseases from the Ministry of Health, Labour and Welfare of Japan, the Life Science Foundation of Japan, the Takeda Science Foundation, Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics, and the Japan Epilepsy Research Foundation (Y.S.).</p>
</ack>
<bio id="epi412085-biog-0001">
<p>
<bold>Satoshi Akamine</bold> is a graduate student in the Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</p>
<graphic id="nlm-graphic-1" orientation="portrait" position="anchor" xlink:href="EPI4-3-81-g002.gif"></graphic>
</bio>
<ref-list content-type="cited-references" id="epi412085-bibl-0001">
<title>References</title>
<ref id="epi412085-bib-0001">
<label>1</label>
<mixed-citation id="epi412085-cit-0001" publication-type="journal">
<string-name>
<surname>Garg</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Green</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Leadbitter</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Neurofibromatosis type 1 and autism spectrum disorder</article-title>. <source/>Pediatrics
<year>2013</year>;<volume>132</volume>:<fpage>1642</fpage>–<lpage>1648</lpage>.</mixed-citation>
</ref>
<ref id="epi412085-bib-0002">
<label>2</label>
<mixed-citation id="epi412085-cit-0002" publication-type="journal">
<string-name>
<surname>Cawthon</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>GF</given-names>
</string-name>, et al. <article-title>A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations</article-title>. <source/>Cell
<year>1990</year>;<volume>62</volume>:<fpage>193</fpage>–<lpage>201</lpage>.<pub-id pub-id-type="pmid">2114220</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0003">
<label>3</label>
<mixed-citation id="epi412085-cit-0003" publication-type="journal">
<string-name>
<surname>Bollag</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Clapp</surname>
<given-names>DW</given-names>
</string-name>, <string-name>
<surname>Shih</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells</article-title>. <source/>Nat Genet
<year>1996</year>;<volume>12</volume>:<fpage>144</fpage>–<lpage>148</lpage>.<pub-id pub-id-type="pmid">8563751</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0004">
<label>4</label>
<mixed-citation id="epi412085-cit-0004" publication-type="journal">
<string-name>
<surname>Pavlowsky</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chelly</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Billuart</surname>
<given-names>P</given-names>
</string-name>. <article-title>Emerging major synaptic signaling pathways involved in intellectual disability</article-title>. <source/>Mol Psychiatry
<year>2012</year>;<volume>17</volume>:<fpage>682</fpage>–<lpage>693</lpage>.<pub-id pub-id-type="pmid">22024764</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0005">
<label>5</label>
<mixed-citation id="epi412085-cit-0005" publication-type="journal">
<string-name>
<surname>Ruggieri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Iannetti</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Clementi</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Neurofibromatosis type 1 and infantile spasms</article-title>. <source/>Childs Nerv Syst
<year>2009</year>;<volume>25</volume>:<fpage>211</fpage>–<lpage>216</lpage>.<pub-id pub-id-type="pmid">18802710</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0006">
<label>6</label>
<mixed-citation id="epi412085-cit-0006" publication-type="journal">
<string-name>
<surname>Kulkantrakorn</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Geller</surname>
<given-names>TJ</given-names>
</string-name>. <article-title>Seizures in neurofibromatosis 1</article-title>. <source/>Pediatr Neurol
<year>1998</year>;<volume>19</volume>:<fpage>347</fpage>–<lpage>350</lpage>.<pub-id pub-id-type="pmid">9880138</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0007">
<label>7</label>
<mixed-citation id="epi412085-cit-0007" publication-type="journal">
<string-name>
<surname>Schaaf</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Gonzalez‐Garay</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Truncating mutations of <italic>MAGEL2</italic> cause Prader‐Willi phenotypes and autism</article-title>. <source/>Nat Genet
<year>2013</year>;<volume>45</volume>:<fpage>1405</fpage>–<lpage>1408</lpage>.<pub-id pub-id-type="pmid">24076603</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0008">
<label>8</label>
<mixed-citation id="epi412085-cit-0008" publication-type="journal">
<string-name>
<surname>Fountain</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Aten</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>MT</given-names>
</string-name>, et al. <article-title>The phenotypic spectrum of Schaaf‐Yang syndrome: 18 new affected individuals from 14 families</article-title>. <source/>Genet Med
<year>2017</year>;<volume>19</volume>:<fpage>45</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">27195816</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0009">
<label>9</label>
<mixed-citation id="epi412085-cit-0009" publication-type="journal">
<string-name>
<surname>Mirzaa</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Paciorkowski</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Marsh</surname>
<given-names>ED</given-names>
</string-name>, et al. <article-title>
<italic>CDKL5</italic> and <italic>ARX</italic> mutations in males with early‐onset epilepsy</article-title>. <source/>Pediatr Neurol
<year>2013</year>;<volume>48</volume>:<fpage>367</fpage>–<lpage>377</lpage>.<pub-id pub-id-type="pmid">23583054</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0010">
<label>10</label>
<mixed-citation id="epi412085-cit-0010" publication-type="journal">
<string-name>
<surname>Rauch</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wieczorek</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Graf</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Range of genetic mutations associated with severe non‐syndromic sporadic intellectual disability: an exome sequencing study</article-title>. <source/>Lancet
<year>2012</year>;<volume>380</volume>:<fpage>1674</fpage>–<lpage>1682</lpage>.<pub-id pub-id-type="pmid">23020937</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0011">
<label>11</label>
<mixed-citation id="epi412085-cit-0011" publication-type="journal">
<string-name>
<surname>Barcia</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Fleming</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Deligniere</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>De novo gain‐of‐function <italic>KCNT1</italic> channel mutations cause malignant migrating partial seizures of infancy</article-title>. <source/>Nat Genet
<year>2012</year>;<volume>44</volume>:<fpage>1255</fpage>–<lpage>1259</lpage>.<pub-id pub-id-type="pmid">23086397</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0012">
<label>12</label>
<mixed-citation id="epi412085-cit-0012" publication-type="journal">
<string-name>
<surname>Claes</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ceulemans</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Audenaert</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>De novo <italic>SCN1A</italic> mutations are a major cause of severe myoclonic epilepsy of infancy</article-title>. <source/>Hum Mutat
<year>2003</year>;<volume>21</volume>:<fpage>615</fpage>–<lpage>621</lpage>.<pub-id pub-id-type="pmid">12754708</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0013">
<label>13</label>
<mixed-citation id="epi412085-cit-0013" publication-type="journal">
<collab collab-type="authors">Epi4K Consortium</collab>
, <collab collab-type="authors">Epilepsy Phenome/Genome Project</collab>
, <string-name>
<surname>Allen</surname>
<given-names>AS</given-names>
</string-name>, et al. <article-title>De novo mutations in epileptic encephalopathies</article-title>. <source/>Nature
<year>2013</year>;<volume>501</volume>:<fpage>217</fpage>–<lpage>221</lpage>.<pub-id pub-id-type="pmid">23934111</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0014">
<label>14</label>
<mixed-citation id="epi412085-cit-0014" publication-type="journal">
<string-name>
<surname>Darke</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Hancock</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi‐centre randomised trial</article-title>. <source/>Arch Dis Child
<year>2010</year>;<volume>95</volume>:<fpage>382</fpage>–<lpage>386</lpage>.<pub-id pub-id-type="pmid">20457702</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0015">
<label>15</label>
<mixed-citation id="epi412085-cit-0015" publication-type="journal">
<string-name>
<surname>Boccaccio</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Glatt‐Deeley</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Watrin</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>The human <italic>MAGEL2</italic> gene and its mouse homologue are paternally expressed and mapped to the Prader‐Willi region</article-title>. <source/>Hum Mol Genet
<year>1999</year>;<volume>8</volume>:<fpage>2497</fpage>–<lpage>2505</lpage>.<pub-id pub-id-type="pmid">10556298</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0016">
<label>16</label>
<mixed-citation id="epi412085-cit-0016" publication-type="journal">
<string-name>
<surname>Matarazzo</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Muscattelli</surname>
<given-names>F</given-names>
</string-name>. <article-title>Natural breaking of the maternal silence at the mouse and human imprinted Prader‐Willi locus: a whisper with functional consequences</article-title>. <source/>Rare Dis
<year>2013</year>;<volume>1</volume>:<fpage>e27228</fpage>.<pub-id pub-id-type="pmid">25003016</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0017">
<label>17</label>
<mixed-citation id="epi412085-cit-0017" publication-type="journal">
<string-name>
<surname>Rieusset</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schaller</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Unmehopa</surname>
<given-names>U</given-names>
</string-name>, et al. <article-title>Stochastic loss of silencing of the imprinted Ndn/NDN allele, in a mouse model and humans with Prader‐Willi syndrome, has functional consequences</article-title>. <source/>PLoS Genet
<year>2013</year>;<volume>9</volume>:<fpage>e1003752</fpage>.<pub-id pub-id-type="pmid">24039599</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0018">
<label>18</label>
<mixed-citation id="epi412085-cit-0018" publication-type="journal">
<string-name>
<surname>van der Bruggen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Traversari</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chomez</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma</article-title>. <source/>Science
<year>1991</year>;<volume>254</volume>:<fpage>1643</fpage>–<lpage>1647</lpage>.<pub-id pub-id-type="pmid">1840703</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0019">
<label>19</label>
<mixed-citation id="epi412085-cit-0019" publication-type="journal">
<string-name>
<surname>Salehi</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Roux</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Kubu</surname>
<given-names>CJ</given-names>
</string-name>, et al. <article-title>NRAGE, a novel MAGE protein, interacts with the p75 neurotrophin receptor and facilitates nerve growth factor‐dependent apoptosis</article-title>. <source/>Neuron
<year>2000</year>;<volume>27</volume>:<fpage>279</fpage>–<lpage>288</lpage>.<pub-id pub-id-type="pmid">10985348</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0020">
<label>20</label>
<mixed-citation id="epi412085-cit-0020" publication-type="journal">
<string-name>
<surname>Vogel</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Brannan</surname>
<given-names>CI</given-names>
</string-name>, <string-name>
<surname>Jenkins</surname>
<given-names>NA</given-names>
</string-name>, et al. <article-title>Loss of neurofibromin results in neurotrophin‐independent survival of embryonic sensory and sympathetic neurons</article-title>. <source/>Cell
<year>1995</year>;<volume>82</volume>:<fpage>733</fpage>–<lpage>742</lpage>.<pub-id pub-id-type="pmid">7671302</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0021">
<label>21</label>
<mixed-citation id="epi412085-cit-0021" publication-type="journal">
<string-name>
<surname>Lupski</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Digenic inheritance and Mendelian disease</article-title>. <source/>Nat Genet
<year>2012</year>;<volume>44</volume>:<fpage>1291</fpage>–<lpage>1292</lpage>.<pub-id pub-id-type="pmid">23192179</pub-id></mixed-citation>
</ref>
<ref id="epi412085-bib-0022">
<label>22</label>
<mixed-citation id="epi412085-cit-0022" publication-type="journal">
<string-name>
<surname>Schaffer</surname>
<given-names>AA</given-names>
</string-name>. <article-title>Digenic inheritance in medical genetics</article-title>. <source/>J Med Genet
<year>2013</year>;<volume>50</volume>:<fpage>641</fpage>–<lpage>652</lpage>.<pub-id pub-id-type="pmid">23785127</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>